First Trust Advisors’s NovoCure NVCR Stock Holding History

First Trust Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92M	Buy	126,596 +32,303	+34%	+$489K	﹤0.01%	2026
2026 Q1	$1.03M	Buy	+94,293	New	+$1.18M	﹤0.01%	2151
2025 Q4	–	Sell	-68,470	Closed	-$885K	–	2690
2025 Q3	$885K	Sell	68,470 -83,803	-55%	-$1.12M	﹤0.01%	2143
2025 Q2	$2.71M	Buy	+152,273	New	+$2.65M	﹤0.01%	1682
2023 Q1	–	Sell	-78,639	Closed	-$5.77M	–	2439
2022 Q4	$5.77M	Buy	78,639 +71,782	+1,047%	+$5.4M	0.01%	1130
2022 Q3	$521K	Buy	+6,857	New	+$535K	﹤0.01%	2194
2022 Q1	–	Sell	-27,455	Closed	-$2.06M	–	2573
2021 Q4	$2.06M	Sell	27,455 -211,948	-89%	-$21.3M	﹤0.01%	1781
2021 Q3	$27.8M	Buy	239,403 +156,541	+189%	+$23.7M	0.03%	655
2021 Q2	$18.4M	Sell	82,862 -111,914	-57%	-$21.8M	0.02%	814
2021 Q1	$25.7M	Sell	194,776 -73,732	-27%	-$11.7M	0.03%	621
2020 Q4	$46.5M	Buy	+268,508	New	+$36.7M	0.06%	439
2020 Q3	–	Sell	-43,744	Closed	-$2.59M	–	2423
2020 Q2	$2.59M	Sell	43,744 -22,248	-34%	-$1.46M	﹤0.01%	1250
2020 Q1	$4.44M	Sell	65,992 -10,472	-14%	-$828K	0.01%	910
2019 Q4	$6.44M	Sell	76,464 -15,520	-17%	-$1.25M	0.01%	992
2019 Q3	$6.88M	Sell	91,984 -4,959	-5%	-$397K	0.01%	935
2019 Q2	$6.13M	Sell	96,943 -2,070	-2%	-$105K	0.01%	955
2019 Q1	$4.77M	Sell	99,013 -8,533	-8%	-$411K	0.01%	1042
2018 Q4	$3.6M	Sell	107,546 -67,662	-39%	-$2.47M	0.01%	1146
2018 Q3	$9.18M	Buy	175,208 +32,543	+23%	+$1.3M	0.02%	863
2018 Q2	$4.46M	Buy	142,665 +28,341	+25%	+$788K	0.01%	1155
2018 Q1	$2.49M	Sell	114,324 -29,831	-21%	-$642K	0.01%	1337
2017 Q4	$2.91M	Buy	+144,155	New	+$2.78M	0.01%	1286

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

First Trust Advisors's NVCR Position: Q2 2026 in Review

First Trust Advisors increased its NovoCure (NVCR) stake by 34% in Q2 2026, buying an estimated $489K and bringing the position to 126,596 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2026.

First Trust Advisors first reported a position in NVCR in Q4 2017 and has held it in 22 quarters since. The position peaked at $46.5M in Q4 2020. 217 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

First Trust Advisors held 126,596 shares of NovoCure worth $1.92M as of Q2 2026.
First Trust Advisors bought 32,303 NovoCure shares in Q2 2026, an estimated $489K.
NovoCure made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2026 holding.
First Trust Advisors first reported a position in NovoCure in Q4 2017 and has held it in 22 quarters since.
First Trust Advisors's NovoCure position peaked at $46.5M in Q4 2020.
217 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.